View Older Stories View More Recent Stories

Mar 20, 2025 11:06PM NVO DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 19, 2025 11:01PM NVO DEADLINE ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 18, 2025 08:23PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 17, 2025 08:18PM ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 16, 2025 06:41PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 15, 2025 06:41PM ROSEN, A TOP RANKED LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 14, 2025 06:36PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 13, 2025 06:31PM NVO DEADLINE; ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 11, 2025 09:23PM ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 10, 2025 04:52PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 9, 2025 03:00PM ROSEN, A LEADING AND RANKED FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 8, 2025 02:15PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 5, 2025 04:30PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Mar 3, 2025 01:56PM ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Feb 27, 2025 01:00PM ROSEN, A LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Feb 25, 2025 03:15PM ROSEN, A LONGSTANDING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Feb 19, 2025 04:10PM ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Feb 18, 2025 12:45PM ROSEN, A LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Feb 16, 2025 11:16AM ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Feb 15, 2025 10:16AM ROSEN, A LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Feb 13, 2025 05:49PM ROSEN, A LEADING NATIONAL FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Feb 11, 2025 09:56PM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Feb 10, 2025 12:09PM ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Feb 9, 2025 09:15AM ROSEN, A LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Feb 5, 2025 08:07PM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Jan 30, 2025 04:39PM ROSEN, A TOP RANKED LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Aug 6, 2024 08:30AM Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033   
Jun 26, 2024 04:11PM 2seventy bio (TSVT) Completes $40M Deal to Sell Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk (NVO)
Mar 14, 2023 08:30AM Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024
Nov 7, 2022 08:00AM Bigfoot Biomedical Announces Insulin Compatibility Expansion to Support Insulin Affordability and Flexibility for People with Diabetes
Sep 1, 2022 08:01AM Forma Therapeutics (FMTX) Acquired by Novo Nordisk for $20/sh or $1.1B
Nov 18, 2021 07:01AM Dicerna Pharma (DRNA) to be Acquired by Novo Nordisk (NVO) for $38.25/share, $3.3 Billion Deal
Nov 5, 2021 08:45AM Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity
Jul 12, 2021 07:02AM Prothena Corp. (PRTA) and Novo Nordisk (NVO) Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
Jul 12, 2021 07:00AM Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
Jun 29, 2021 08:25AM Walmart (WMT) Announces Launch of the First and Only Private Brand Analog Insulin
Mar 18, 2021 06:17AM Gilead Sciences (GILD), Novo Nordisk (NVO) Expand NASH Clinical Collaboration
Mar 15, 2021 09:23AM Data from STEP clinical trial program evaluating effect of semaglutide 2.4 mg in people with obesity to be presented at 2021 ENDO annual meeting
Jan 4, 2021 09:14AM Novo Nordisk extends COVID-19 Patient Assistance Program, encourages people facing affordability challenges to visit NovoCare.com
Dec 4, 2020 09:33PM FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17
Nov 15, 2020 05:30PM Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
Nov 5, 2020 10:03AM Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioral therapy
Apr 14, 2020 02:43PM Novo Nordisk offers free 90-day insulin supply to people experiencing financial hardship due to COVID-19
Apr 2, 2020 01:20PM Coronavirus (COVID-19) resources available from Novo Nordisk in the US
Jan 2, 2020 09:14AM Novo Nordisk's new insulin affordability offerings now available in the US
Nov 19, 2019 08:50AM New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic
Nov 18, 2019 06:17AM Dicerna Pharma (DRNA), Novo Nordisk (NVO) Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases
Oct 9, 2019 08:03AM bluebird bio (BLUE), Novo Nordisk (NVO) Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
Sep 6, 2019 07:55AM Novo Nordisk launching additional US insulin affordability offerings in January 2020
Aug 14, 2019 01:00PM Calling life science innovators: don't miss your chance for a "Golden Ticket" to LabCentral
View More Recent Stories View Older Stories